Core Insights - SELLAS Life Sciences Group is advancing its clinical programs for Galinpepimut-S (GPS) and SLS009 in Acute Myeloid Leukemia (AML), with 2026 expected to be a pivotal year for the company [2] - The company reported a cash position of $71.8 million as of December 31, 2025, with an additional $42.6 million received from warrant exercises in Q1 2026, marking its strongest financial position in history [12][15] Clinical Developments - The Phase 3 REGAL trial of GPS is nearing its final analysis, with 72 events recorded as of December 26, 2025, and the company is awaiting the pre-specified 80 events to proceed with statistical analysis and unblinding [4] - The first patient has been dosed in the Phase 2 trial of SLS009 for newly diagnosed first-line AML patients, following positive Phase 2 results in relapsed/refractory AML presented at ASH 2025 [2][7] - SLS009 demonstrated a 46% overall response rate in a Phase 2 study for relapsed/refractory AML, with a median overall survival of 8.9 months in the least pretreated cohort [5][6] Financial Performance - Research and development expenses decreased to $16.0 million in 2025 from $19.1 million in 2024, primarily due to reduced clinical trial expenses [13] - General and administrative expenses slightly decreased to $12.3 million in 2025 from $12.4 million in 2024 [14] - The net loss for 2025 was $26.9 million, an improvement from a net loss of $30.9 million in 2024, with a basic and diluted loss per share of $0.25 [15] Strategic Collaborations - In January 2026, SELLAS entered a strategic collaboration with IMPACT-AML to expand the SLS009 clinical program in Europe, with an anticipated enrollment of approximately 40 patients [3]

Core Insights - SELLAS Life Sciences Group, Inc. announced promising preclinical data for SLS009 (tambiciclib), a selective CDK9 inhibitor, which will be presented at the AACR conference [1][4] Group 1: Preclinical Data - SLS009 lowers the apoptotic threshold in acute myeloid leukemia (AML) cells by suppressing critical survival pathways, leading to increased apoptosis [1][4] - Exposure of AML cell lines to SLS009 showed a decrease in MCL-1 expression and an increase in active caspase-3 levels, indicating enhanced potency with repeated exposure [2][4] - The IC50 of SLS009 decreased from 50 nM to about 20 nM with repeated treatment, demonstrating its effectiveness [2] Group 2: Clinical Implications - SLS009 exhibited activity in AML models with ASXL1 and TP53 mutations, which are typically associated with poor clinical outcomes [3] - The ability of SLS009 to target AML cell survival mechanisms across diverse molecular subtypes supports its development for combination therapies [4] Group 3: Presentation Details - The poster presentation titled "Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines" will take place on April 21, 2026, at the AACR conference [5]

Core Insights - SELLAS Life Sciences Group has initiated a Phase 2 trial for SLS009 (tambiciclib), a CDK9 inhibitor, targeting newly diagnosed acute myeloid leukemia (AML) patients [1][2] - The trial aims to enroll approximately 80 patients, focusing on two cohorts with high unmet medical needs [2] - Topline data from the trial is expected in Q4 2026 [1] Group 1: Trial Details - The trial, designated NCT04588922, includes a predictive biomarker cohort and an early resistance cohort [4] - The predictive biomarker cohort targets newly diagnosed patients unlikely to benefit from standard venetoclax/azacitidine therapy based on molecular profiling [4] - The early resistance cohort includes patients who show no response after two cycles of aza/ven treatment [4] Group 2: Previous Results and Efficacy - In a completed Phase 2 trial for relapsed/refractory (r/r) AML, SLS009 combined with aza/ven met all endpoints, achieving an overall response rate (ORR) of 33% across all evaluable patients [3][5] - The ORR was 40% for the recommended 30mg BIW dose level, with specific subgroups showing even higher response rates: 44% in AML patients with myelodysplasia-related changes and 50% in ASXL1-mutated AML patients [5] - Median overall survival (mOS) for patients treated with the 30mg BIW dose was reported at 8.8 months, significantly higher than the 2.4 months with the best available therapy [5] Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [3] - The company's lead product candidate, GPS, targets the WT1 protein and has potential applications in both hematologic malignancies and solid tumors [3] - SLS009 is positioned as a potentially first and best-in-class CDK9 inhibitor, aiming to offer reduced toxicity and increased potency compared to existing options [3]

Core Insights - SELLAS Life Sciences Group has entered into an agreement with IMPACT-AML to conduct a clinical study evaluating SLS009, a selective CDK9 inhibitor, for acute myeloid leukemia (AML) [1][3] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications, with its lead product candidate, GPS, targeting the WT1 protein [4] - SLS009 is positioned as a potentially first and best-in-class small molecule CDK9 inhibitor, showing high response rates in AML patients with unfavorable prognostic factors [4] Collaboration Details - The IMPACT-AML initiative is a pan-European project aimed at advancing innovative treatments for AML, involving major research and clinical institutions across Europe [2] - The collaboration allows SELLAS to leverage IMPACT-AML's infrastructure for efficient patient enrollment and access to multiple European clinical sites [2][3] Clinical Study Plans - The clinical study will evaluate SLS009 in combination with azacitidine and venetoclax (AZA/VEN) in approximately 40 newly diagnosed AML patients with high-risk features [3][6] - Enrollment at U.S. sites is expected to begin in Q1 2026, followed by European sites in Q2 2026, pending regulatory and site readiness [3][6]

Core Viewpoint - SELLAS Life Sciences Group, Inc. is advancing its Phase 3 REGAL trial for GPS as a potential maintenance therapy in patients with acute myeloid leukemia (AML) after second complete remission, with the trial currently reporting 72 events as of December 26, 2025, and awaiting the 80 events needed for final analysis [1][3][7] Group 1: Trial Update - The Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 REGAL trial continue without modification, with expectations that the required 80 events (deaths) for final analysis would occur before year-end [2] - As of December 26, 2025, the trial has recorded 72 events, and SELLAS remains blinded to all efficacy and survival data outcomes, meaning this update does not affect future statistical analyses [3][7] - The final analysis is event-driven, and the company will announce when the 80th event occurs [3][7] Group 2: Company Commitment and Expert Insights - The CEO of SELLAS expressed appreciation for the dedication of participants in the REGAL trial, noting that survival times appear longer than expected, which may increase the probability of a successful study [4] - Dr. Yair Levy, a member of the REGAL Steering Committee, highlighted the significance of the REGAL study in evaluating GPS for AML patients who cannot undergo transplant, with an expected median overall survival of around eight months for current treatments [4] - The company is committed to advancing breakthrough therapies like GPS that have the potential to significantly improve patient outcomes in AML [4] Group 3: About the REGAL Trial - The REGAL trial (NCT04229979) is a Phase 3 randomized registrational clinical trial for GPS in AML patients who have achieved complete remission following second-line salvage therapy [5] - The primary endpoint of the trial is overall survival, and the IDMC is responsible for monitoring patient safety and efficacy data [5] Group 4: About SELLAS Life Sciences - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for various cancer indications, with its lead product candidate GPS targeting the WT1 protein present in multiple tumor types [6] - The company is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [8]

Core Insights - SELLAS Life Sciences Group, Inc. announced promising clinical data for SLS009, a CDK9 inhibitor, in combination with azacitidine and venetoclax for treating relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes [1][3] Group 1: Clinical Study Details - The Phase 2 study involved 35 evaluable patients with a median age of 69, where 98% had ELN adverse-risk AML, with common mutations including ASXL1, RUNX1, TP53, and SRSF2 [2] - The overall response rate for SLS009 in combination with AZA/VEN was 46%, with 29% achieving complete response (CR) or CR with incomplete blood count recovery (CRi) [3] - Patients with ASXL1 and TP53 mutations had response rates of 48% and 57%, respectively, with median overall survival (mOS) significantly exceeding the expected 2.6 months [3] Group 2: Safety and Tolerability - No dose-limiting toxicities (DLTs) or treatment-related deaths were reported, indicating that the combination therapy was well tolerated [3][5] - The combination therapy demonstrated a median overall survival of 8.9 months in the least pretreated cohort, with a 58% response rate in patients with one prior line of therapy [5] Group 3: Future Plans and Implications - The company plans to expand the study to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features in Q1 2026 [5] - The results suggest that SLS009 may effectively overcome resistance to venetoclax-based regimens by targeting MCL-1, a key resistance mechanism in AML [4]

Core Insights - SELLAS Life Sciences Group, Inc. reported positive developments in its clinical programs, particularly for SLS009 and GPS, with significant upcoming milestones and a strong financial position [1][2][3] Financial Performance - As of September 30, 2025, the company had cash and cash equivalents totaling approximately $44.3 million, with an additional $29.1 million received from warrant exercises in October 2025 [1][11] - Research and development expenses for Q3 2025 were $4.2 million, a decrease from $4.4 million in Q3 2024, primarily due to reduced clinical trial expenses [8] - General and administrative expenses for Q3 2025 were $2.9 million, slightly down from $3.0 million in Q3 2024, attributed to lower professional fees [9] - The net loss for Q3 2025 was $6.8 million, or a loss per share of $0.06, compared to a net loss of $7.1 million, or $0.10 per share, in Q3 2024 [10][16] Clinical Developments - The Phase 3 REGAL trial of GPS is progressing as planned, with a final analysis expected by year-end 2025 after reaching 80 events [3] - Positive Phase 2 data for SLS009 in relapsed/refractory AML has been accepted for presentation at the ASH Annual Meeting in December 2025, with plans for an 80-patient trial in newly diagnosed AML patients expected to start in Q1 2026 [4][6] - Preclinical data presented at ESMO 2025 showed significant survival benefits of SLS009 in T-cell prolymphocytic leukemia (T-PLL), supporting its potential across various hematologic malignancies [5] Corporate Events - A virtual R&D Day was held on October 29, 2025, showcasing the company's ongoing clinical trials and receiving positive feedback from key opinion leaders [6] - The company raised approximately $54.6 million in gross proceeds from warrant exercises in September and October 2025, enhancing its financial foundation [7]

Core Insights - SELLAS Life Sciences Group, Inc. is advancing its late-stage clinical biopharmaceutical development, particularly focusing on SLS009 for relapsed or refractory acute myeloid leukemia (r/r AML) [1][2] - The Phase 2 study of SLS009 will be presented at the upcoming ASH Annual Meeting, highlighting its potential in combination with azacitidine and venetoclax [1][3] - The company emphasizes the growing evidence supporting SLS009's efficacy across hematologic malignancies, with preclinical data demonstrating its cytotoxic effects on AML cell lines [2][4] Company Overview - SELLAS is a late-stage clinical biopharmaceutical company dedicated to developing novel therapies for various cancer indications, with a lead product candidate, GPS, targeting the WT1 protein [4] - SLS009, a CDK9 inhibitor, is positioned as a potentially first-in-class treatment with reduced toxicity and increased potency compared to existing CDK9 inhibitors [4] - The company aims to address significant unmet needs in treating difficult-to-manage cancers, particularly in patients with unfavorable prognostic factors like ASXL1 mutations [4]

Core Viewpoint - SELLAS Life Sciences Group, Inc. has announced the immediate exercise of existing warrants, resulting in gross cash proceeds of approximately $31.0 million for the purchase of up to 22,363,714 shares of common stock [1][2]. Group 1: Financial Transaction - The immediate exercise of the existing warrants will provide the company with gross cash proceeds of about $31.0 million [1]. - Investors exercising the existing warrants will receive new registered warrants to purchase the same number of shares at an exercise price of $2.00, which will be exercisable immediately and will expire five years from issuance [2]. - The transaction is expected to close on or about October 28, 2025, pending customary closing conditions [2]. Group 2: Advisory and Registration - A.G.P./Alliance Global Partners and Maxim Group LLC acted as financial advisors for this transaction [3]. - The offering is being made under an effective shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission [4]. Group 3: Company Overview - SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [7]. - The company's lead product candidate, GPS, targets the WT1 protein and has potential applications in treating a wide range of hematologic malignancies and solid tumors [7]. - SELLAS is also developing SLS009, a differentiated small molecule CDK9 inhibitor, which has shown a high response rate in AML patients with unfavorable prognostic factors [7]. Group 4: Upcoming Events - SELLAS will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders and company management to discuss the treatment landscape for acute myeloid leukemia [5].

Company Overview - SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for various cancer indications [2] - The lead product candidate, GPS, targets the WT1 protein found in multiple tumor types and has potential as both a monotherapy and in combination with other therapies [2] - The company is also developing SLS009 (tambiciclib), a differentiated small molecule CDK9 inhibitor, which shows a high response rate in AML patients with unfavorable prognostic factors [2] Event Participation - Dr. Angelos Stergiou, President and CEO of SELLAS, will participate in the J.P. Morgan U.S. Opportunities Forum on November 12, 2025 [1] - The event will take place at the Kimpton EPIC Hotel in Miami, Florida, and will consist of 1x1 investor meetings [2]